Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 323.5 DKK 0.19% Market Closed
Market Cap: 84.9B DKK

EV/EBIT
Enterprise Value to EBIT

32.7
Current
32.2
Median
3.8
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
32.7
=
Enterprise Value
80.8B DKK
/
EBIT
2.5B DKK
EBIT Growth EV/EBIT to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBIT: 21.6
32.7
123%
0.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 301.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.1
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.3
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -537.4 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -310.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
9.9
2-Years Forward
EV/EBIT
8.4
3-Years Forward
EV/EBIT
6.8